JP2016504290A5 - - Google Patents

Download PDF

Info

Publication number
JP2016504290A5
JP2016504290A5 JP2015544124A JP2015544124A JP2016504290A5 JP 2016504290 A5 JP2016504290 A5 JP 2016504290A5 JP 2015544124 A JP2015544124 A JP 2015544124A JP 2015544124 A JP2015544124 A JP 2015544124A JP 2016504290 A5 JP2016504290 A5 JP 2016504290A5
Authority
JP
Japan
Prior art keywords
diamine
fluoro
benzimidazol
pyrimidine
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015544124A
Other languages
English (en)
Japanese (ja)
Other versions
JP6412503B2 (ja
JP2016504290A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/071132 external-priority patent/WO2014081906A2/en
Publication of JP2016504290A publication Critical patent/JP2016504290A/ja
Publication of JP2016504290A5 publication Critical patent/JP2016504290A5/ja
Application granted granted Critical
Publication of JP6412503B2 publication Critical patent/JP6412503B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015544124A 2012-11-21 2013-11-21 置換逆ピリミジンBmi−1阻害剤 Active JP6412503B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21
US61/728,907 2012-11-21
PCT/US2013/071132 WO2014081906A2 (en) 2012-11-21 2013-11-21 Substituted reverse pyrimidine bmi-1 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018183173A Division JP6617186B2 (ja) 2012-11-21 2018-09-28 置換逆ピリミジンBmi−1阻害剤

Publications (3)

Publication Number Publication Date
JP2016504290A JP2016504290A (ja) 2016-02-12
JP2016504290A5 true JP2016504290A5 (enExample) 2017-01-05
JP6412503B2 JP6412503B2 (ja) 2018-10-24

Family

ID=50776672

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2015544124A Active JP6412503B2 (ja) 2012-11-21 2013-11-21 置換逆ピリミジンBmi−1阻害剤
JP2018183173A Active JP6617186B2 (ja) 2012-11-21 2018-09-28 置換逆ピリミジンBmi−1阻害剤
JP2019203706A Active JP6918898B2 (ja) 2012-11-21 2019-11-11 置換逆ピリミジンBmi−1阻害剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2018183173A Active JP6617186B2 (ja) 2012-11-21 2018-09-28 置換逆ピリミジンBmi−1阻害剤
JP2019203706A Active JP6918898B2 (ja) 2012-11-21 2019-11-11 置換逆ピリミジンBmi−1阻害剤

Country Status (32)

Country Link
US (3) US10428050B2 (enExample)
EP (1) EP2922828B1 (enExample)
JP (3) JP6412503B2 (enExample)
KR (4) KR20220143164A (enExample)
CN (2) CN111423417B (enExample)
AR (1) AR093579A1 (enExample)
AU (1) AU2013348009C1 (enExample)
BR (1) BR112015011760B1 (enExample)
CA (1) CA2892045C (enExample)
CL (1) CL2015001377A1 (enExample)
CR (1) CR20150294A (enExample)
CU (1) CU24387B1 (enExample)
DK (1) DK2922828T3 (enExample)
EA (2) EA035349B1 (enExample)
EC (1) ECSP15019948A (enExample)
ES (1) ES2821529T3 (enExample)
HK (1) HK1215032A1 (enExample)
IL (2) IL238871B (enExample)
MA (1) MA38208B1 (enExample)
MX (2) MX385385B (enExample)
NI (1) NI201500072A (enExample)
NZ (2) NZ746607A (enExample)
PE (1) PE20151413A1 (enExample)
PH (1) PH12015501130B1 (enExample)
PL (1) PL2922828T3 (enExample)
PT (1) PT2922828T (enExample)
SA (1) SA517381847B1 (enExample)
SG (2) SG10201600149VA (enExample)
TW (1) TWI623531B (enExample)
UA (1) UA118094C2 (enExample)
WO (1) WO2014081906A2 (enExample)
ZA (1) ZA201503642B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035349B1 (ru) 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
CA2917671A1 (en) * 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer
WO2015030847A1 (en) 2013-08-30 2015-03-05 Ptc Therapeutics, Inc. Substituted pyrimidine bmi-1 inhibitors
WO2015076800A1 (en) 2013-11-21 2015-05-28 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine bmi-1 inhibitors
EP3335126B1 (en) 2015-08-11 2026-03-11 Cognoa, Inc. Apparatus to determine developmental progress with artificial intelligence and user input
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
US20190016680A1 (en) * 2016-01-14 2019-01-17 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
CN118609834A (zh) 2016-11-14 2024-09-06 科格诺亚公司 用于评估发育状况并提供覆盖度和可靠性控制的方法和装置
EP3580700A4 (en) 2017-02-09 2020-11-18 Cognoa, Inc. PLATFORM AND SYSTEM FOR DIGITAL PERSONALIZED MEDICINE
EP3664803A4 (en) 2017-08-01 2021-05-05 PTC Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
AU2019340402B2 (en) * 2018-08-17 2025-04-03 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
BR112021013913A2 (pt) 2019-01-15 2021-09-21 Ptc Therapeutics, Inc. Método para tratar uma leucemia mieloide aguda
AU2020227748A1 (en) * 2019-02-28 2021-09-16 Ptc Therapeutics, Inc. Method for treating a multiple myeloma
EP3938368B1 (en) * 2019-03-11 2023-06-07 PTC Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof
BR112021018770A2 (pt) 2019-03-22 2022-02-15 Cognoa Inc Métodos e dispositivos de terapia digital personalizada
CA3134648A1 (en) * 2019-03-27 2020-10-01 Ptc Therapeutics, Inc. Combinations useful in a method for treating sarcoma
CA3135929A1 (en) * 2019-04-02 2020-10-08 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators
US12564342B2 (en) 2019-09-06 2026-03-03 Cognoa, Inc. Methods, systems, and devices for the diagnosis of behavioral disorders, developmental delays, and neurologic impairments
CN116917009A (zh) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 用于粒子治疗系统的机架
US20240120050A1 (en) * 2022-10-07 2024-04-11 Insight Direct Usa, Inc. Machine learning method for predicting a health outcome of a patient using video and audio analytics

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
CN1102144C (zh) 1994-08-13 2003-02-26 株式会社柳韩洋行 新的嘧啶衍生物及其制备方法
IN188411B (enExample) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
ATE396978T1 (de) 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
ES2254238T3 (es) 1999-10-27 2006-06-16 Novartis Ag Compuestos de tiazol e imidazo(4,5-b)piridina y su uso farmaceutico.
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
DK1330452T3 (da) 2000-09-20 2009-03-16 Ortho Mcneil Janssen Pharm Pyrazinderivater som modulatorer af tyrosinkinaser
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
US7163940B2 (en) 2000-12-15 2007-01-16 Smithkline Beecham Corporation Pyrazolopyridinyl pyrimidine therapeutic compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
WO2003004492A1 (en) 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
US7109204B2 (en) 2001-08-01 2006-09-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
WO2003099811A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
EP1533304B1 (en) 2002-06-28 2009-11-04 Nippon Shinyaku Co., Ltd. Amide derivative
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
US7060850B2 (en) * 2002-07-11 2006-06-13 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
US7582630B2 (en) 2002-10-15 2009-09-01 Smithkline Beecham Corporation Pyradazine compounds as GSK-3 inhibitors
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
DK1704145T3 (da) 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
WO2005076854A2 (en) 2004-02-04 2005-08-25 Smithkline Beecham Corporation Pyrimidinone compounds useful as kinase inhibitors
NZ584499A (en) * 2004-03-30 2011-08-26 Vertex Pharma Azaindoles Useful as Inhibitors of Jak and Other Protein Kinases
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR100917511B1 (ko) 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Syk 저해 활성을 갖는 신규한 아미노피리딘 화합물
GT200600105A (es) 2005-03-10 2007-02-14 Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos.
EP2044051B1 (en) 2006-06-22 2010-01-27 BIOVITRUM AB (publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
CN101516873A (zh) 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
WO2008040753A1 (en) * 2006-10-03 2008-04-10 Neurosearch A/S Indazolyl derivatives useful as potassium channel modulating agents
MX2009004019A (es) * 2006-10-19 2009-06-19 Signal Pharm Llc Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
AU2007336933A1 (en) 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
CL2008000197A1 (es) 2007-01-26 2008-08-01 Smithkline Beecham Corp Compuestos derivados de 2,4-diamino pirimidina, inhibidores de antranilamida de cinasa aurora; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
TW200846344A (en) 2007-04-25 2008-12-01 Astrazeneca Ab Chemical compounds
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
US8415358B2 (en) 2007-09-17 2013-04-09 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
ES2569528T3 (es) 2007-11-16 2016-05-11 Incyte Holdings Corporation 4-pirazolil-N-arilpirimidin-2-aminas y 4-pirazolil-N-heteroarilpirimidin-2-aminas como inhibidores de quinasas Janus
CA2707989A1 (en) 2007-12-07 2009-06-11 Novartis Ag Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
JP2011518219A (ja) 2008-04-22 2011-06-23 ポートラ ファーマシューティカルズ, インコーポレイテッド タンパク質キナーゼの阻害剤
ES2605815T3 (es) * 2008-07-01 2017-03-16 Ptc Therapeutics, Inc. Moduladores de la expresión de la proteína Bmi-1
ES2378513T3 (es) 2008-08-06 2012-04-13 Pfizer Inc. Compuestos 2-heterociclilamino piracinas sustituidas en posición 6 como inhibidores de CHK-1
JP2012501308A (ja) * 2008-09-02 2012-01-19 ノイロサーチ アクティーゼルスカブ ピラゾリルピリミジン誘導体及びカリウムチャネルモジュレーターとしてのそれらの使用
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
KR20110120286A (ko) 2009-02-12 2011-11-03 아스텔라스세이야쿠 가부시키가이샤 헤테로환 유도체
US8461158B2 (en) 2009-03-27 2013-06-11 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
WO2010144416A1 (en) 2009-06-08 2010-12-16 Gaeta Federico C A SUBSTITUTED PYRAZOLO [1,5-a] PYRIDINE COMPOUNDS HAVING MULTI-TARGET ACTIVITY
GEAP202213376A (en) * 2009-06-17 2022-02-25 Vertex Pharmaceuticals Incorporated Us Inhibitors of influenza viruses replication
US8486939B2 (en) 2009-07-07 2013-07-16 Pathway Therapeutics Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
CA2767089A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
ES2483594T3 (es) 2009-07-15 2014-08-06 Abbott Laboratories Pirrolopirazinas inhibidoras de quinasas
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
CN102812022B (zh) 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
KR20160033798A (ko) * 2010-08-19 2016-03-28 에프. 호프만-라 로슈 아게 체세포의 유도된 재프로그래밍된 신경 줄기 세포 (irnscs) 로의 전환
SI2616465T1 (sl) 2010-09-13 2016-02-29 Novartis Ag Triazin-oksadiazoli
WO2012050884A2 (en) 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
MX2013006467A (es) 2010-12-09 2013-10-01 Amgen Inc Compuestos biciclicos como inhibidores pim.
DK2678332T3 (en) 2011-02-25 2016-08-15 Yuhan Corp Diaminopyrimidine derivatives and process for their preparation
AU2012280725B2 (en) * 2011-07-07 2017-02-02 Merck Patent Gmbh Substituted azaheterocycles for the treatment of cancer
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EA035349B1 (ru) * 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3938368B1 (en) * 2019-03-11 2023-06-07 PTC Therapeutics, Inc. Compound form having enhanced bioavailability and formulations thereof

Similar Documents

Publication Publication Date Title
JP2016504290A5 (enExample)
JP2016529292A5 (enExample)
US11135201B2 (en) Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof
JP6728321B2 (ja) 置換ピリミジンBmi−1阻害剤
US10421761B2 (en) Compounds for kinase modulation, and indications therefor
DK2935248T3 (en) RELATIONS AND PROCEDURE FOR CHINESE MODULATION AND INDICATIONS THEREOF
US9771369B2 (en) Compounds and methods for kinase modulation, and indications therefor
JP5815558B2 (ja) キナーゼ調節のための化合物及び方法ならびにそれらの適応症
JP2015511224A5 (enExample)
JP2025134754A (ja) Egfr変異を有するがんを処置するためのアミノ置換ヘテロ環類
RU2020112759A (ru) Гетероциклические соединения в качестве ингибиторов PAD
JP2015517988A5 (enExample)
NZ607060A (en) Substituted imidazoquinoline derivatives as kinase inhibitors
JP2014526526A5 (enExample)
US10925880B2 (en) Combination of PI3K-inhibitors
WO2018195471A1 (en) Syk inhibitors in combination with hypomethylating agents
JP2024529485A (ja) イミダゾ[1,2-b]ピリダジニル化合物及びその使用